Cat. No.: HY-13594

Chlorin e6

(Synonyms: Ce6)

20 Cited Publications

고객리뷰

Based on 20 publication(s) in Google Scholar

Chlorin e6 is a photosensitizer and has strong absorption peaks at wavelength of 402 and 662 nm, as well as exhibiting intense fluorescence at 668 nm. Chlorin e6 has antimicrobial efficacy and anticancer activity. Chlorin e6 induces cell apoptosis via caspase-3 activation and can be used for the research of cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.51%
CAS No.: 19660-77-6
화학식: C₃₄H₃₆N₄O₆
분자량:596.67

보관:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Chlorin e6 Chemical Structure

CAS No.: 19660-77-6

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (20)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

All PARP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
B16-F10	IC₅₀	>50 μM Compound: Ce6	Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay	[PMID: 37204432]
B16-F10	IC₅₀	1.57 μM Compound: Chlorin e6	Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	1.67 μM Compound: Chlorin e6	Photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay Photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	23.81 μM Compound: Chlorin e6	Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay Cytotoxicity against mouse B16-F10 cells incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
B16-F10	IC₅₀	2305 nM Compound: Ce6	Photodynamic cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay Photodynamic cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay	[PMID: 37204432]
B16-F10	IC₅₀	26.54 μM Compound: Chlorin e6	Photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition by CCK-8 assay Photodynamic antitumor activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
HeLa	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human HeLa cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay Antiproliferative activity against human HeLa cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay	[PMID: 38118394]
HeLa	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human HeLa cells under dark condition by CCK8 assay Antiproliferative activity against human HeLa cells under dark condition by CCK8 assay	[PMID: 38118394]
HeLa	IC₅₀	>50 μM Compound: Ce6	Dark toxicity in human HeLa cells assessed as reduction in cell viability after 3 hrs by MTT assay Dark toxicity in human HeLa cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 32787080]
HeLa	IC₅₀	>50 μM Compound: Ce6	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay	[PMID: 37204432]
HeLa	IC₅₀	>50 μM Compound: Ce6	Dark cytotoxicity against human HeLa cells assessed as inhibition of cell viability incubated for 3 hrs by CCK8 assay Dark cytotoxicity against human HeLa cells assessed as inhibition of cell viability incubated for 3 hrs by CCK8 assay	[PMID: 39167079]
HeLa	IC₅₀	1.92 μM Compound: Ce6	Phototoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 3 hrs followed by 54 J/cm2 light irradiation and measured after 24 hrs by MTT assay Phototoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 3 hrs followed by 54 J/cm2 light irradiation and measured after 24 hrs by MTT assay	[PMID: 32787080]
HeLa	IC₅₀	955 nM Compound: Ce6	Photodynamic cytotoxicity against human HeLa cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay Photodynamic cytotoxicity against human HeLa cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay	[PMID: 37204432]
HeLa	IC₅₀	955 nM Compound: Ce6	Phototoxicity against human HeLa cells assessed as inhibition of cell viability preincubated for 3 hrs followed by photo-irradiation of 54 J/cm2 for 24 hrs by CCK8 assay Phototoxicity against human HeLa cells assessed as inhibition of cell viability preincubated for 3 hrs followed by photo-irradiation of 54 J/cm2 for 24 hrs by CCK8 assay	[PMID: 39167079]
HEp-2	IC₅₀	>400 μM Compound: 5	Cytotoxicity against human Hep2 cells under dark condition after 18 hrs by celltiter blue assay Cytotoxicity against human Hep2 cells under dark condition after 18 hrs by celltiter blue assay	[PMID: 21936519]
HEp-2	IC₅₀	20.8 μM Compound: 5	Cytotoxicity against human Hep2 cells after overnight incubation followed by cells irradiated with 1 J/cm'2 light for 20 mins measured after overnight incubation by celltiter blue assay Cytotoxicity against human Hep2 cells after overnight incubation followed by cells irradiated with 1 J/cm'2 light for 20 mins measured after overnight incubation by celltiter blue assay	[PMID: 21936519]
HepG2	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human HepG2 cells under dark condition by CCK8 assay Antiproliferative activity against human HepG2 cells under dark condition by CCK8 assay	[PMID: 38118394]
HepG2	IC₅₀	>50 μM Compound: Ce6	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay	[PMID: 37204432]
HepG2	IC₅₀	>50 μM Compound: Ce6	Dark cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 3 hrs by CCK8 assay Dark cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 3 hrs by CCK8 assay	[PMID: 39167079]
HepG2	IC₅₀	1.38 μM Compound: Chlorin e6	Cytotoxicity against human HepG2 cells incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	1.66 μM Compound: Chlorin e6	Photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay Photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under 10 J/cm2 light irradiation at 660 nm by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	16 μM Compound: 1	Antiproliferative activity against human HepG2 cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay Antiproliferative activity against human HepG2 cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay	[PMID: 38118394]
HepG2	IC₅₀	41.2 μM Compound: Chlorin e6	Photo cytotoxic activity against human HepG2 cells irradiated with 1.7 J/cm'2 light dose for 10 mins measured after overnight incubation by MTT assay Photo cytotoxic activity against human HepG2 cells irradiated with 1.7 J/cm'2 light dose for 10 mins measured after overnight incubation by MTT assay	[PMID: 26306981]
HepG2	IC₅₀	41.53 μM Compound: Chlorin e6	Photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition by CCK-8 assay Photodynamic antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	50.4 μM Compound: Chlorin e6	Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay Cytotoxicity against human HepG2 cells incubated for 48 hrs under dark condition by CCK-8 assay	[PMID: 37690263]
HepG2	IC₅₀	52.9 μM Compound: Chlorin e6	Dark toxicity in human HepG2 cells after overnight incubation by MTT assay Dark toxicity in human HepG2 cells after overnight incubation by MTT assay	[PMID: 26306981]
HepG2	IC₅₀	598.6 nM Compound: Ce6	Photodynamic cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay Photodynamic cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay	[PMID: 37204432]
HepG2	IC₅₀	598.6 nM Compound: Ce6	Phototoxicity against human HepG2 cells assessed as inhibition of cell viability preincubated for 3 hrs followed by photo-irradiation of 54 J/cm2 for 24 hrs by CCK8 assay Phototoxicity against human HepG2 cells assessed as inhibition of cell viability preincubated for 3 hrs followed by photo-irradiation of 54 J/cm2 for 24 hrs by CCK8 assay	[PMID: 39167079]
Huh-7	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human Huh-7 cells under dark condition by CCK8 assay Antiproliferative activity against human Huh-7 cells under dark condition by CCK8 assay	[PMID: 38118394]
Huh-7	IC₅₀	18 μM Compound: 1	Antiproliferative activity against human Huh-7 cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay Antiproliferative activity against human Huh-7 cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay	[PMID: 38118394]
HUVEC	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human HUVEC cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay Antiproliferative activity against human HUVEC cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay	[PMID: 38118394]
HUVEC	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against human HUVEC cells under dark condition by CCK8 assay Antiproliferative activity against human HUVEC cells under dark condition by CCK8 assay	[PMID: 38118394]
HUVEC	IC₅₀	>50 μM Compound: Ce6	Cytotoxicity against HUVEC cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay Cytotoxicity against HUVEC cells assessed as inhibition of cell viability under dark condition incubated for 27 hrs by CCK8 assay	[PMID: 37204432]
HUVEC	IC₅₀	799.2 nM Compound: Ce6	Photodynamic cytotoxicity against HUVEC cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay Photodynamic cytotoxicity against HUVEC cells assessed as inhibition of cell viability incubated for 3 hrs followed by photo-irradiation at 54 J/cm2 measured after 24 hrs by CCK8 assay	[PMID: 37204432]
MCF7	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human MCF7 cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay Antiproliferative activity against human MCF7 cells under 10 J/cm2 light irradiation at 660 nm by CCK8 assay	[PMID: 38118394]
MCF7	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human MCF7 cells under dark condition by CCK8 assay Antiproliferative activity against human MCF7 cells under dark condition by CCK8 assay	[PMID: 38118394]
MCF7	IC₅₀	>50 μM Compound: Ce6	Dark toxicity in human MCF7 cells assessed as reduction in cell viability after 3 hrs by MTT assay Dark toxicity in human MCF7 cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 32787080]
MCF7	IC₅₀	3.4 μM Compound: Ce6	Phototoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 3 hrs followed by 54 J/cm2 light irradiation and measured after 24 hrs by MTT assay Phototoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 3 hrs followed by 54 J/cm2 light irradiation and measured after 24 hrs by MTT assay	[PMID: 32787080]
SK-OV-3	IC₅₀	0.39 μM Compound: Chlorine E6	Photocytotoxicity in human SKOV3 cells assessed as cell death incubated for 6 hrs followed by PDT-1200 light irradiation at 20 J/cm2 measured after 16 hrs using liposome-encapsulated compound by MTT assay Photocytotoxicity in human SKOV3 cells assessed as cell death incubated for 6 hrs followed by PDT-1200 light irradiation at 20 J/cm2 measured after 16 hrs using liposome-encapsulated compound by MTT assay	[PMID: 29670694]
SW480	IC₅₀	>50 μM Compound: Ce6	Dark toxicity in human SW480 cells assessed as reduction in cell viability after 3 hrs by MTT assay Dark toxicity in human SW480 cells assessed as reduction in cell viability after 3 hrs by MTT assay	[PMID: 32787080]
SW480	IC₅₀	3.1 μM Compound: Ce6	Phototoxicity against human SW480 cells assessed as reduction in cell viability preincubated for 3 hrs followed by 54 J/cm2 light irradiation and measured after 24 hrs by MTT assay Phototoxicity against human SW480 cells assessed as reduction in cell viability preincubated for 3 hrs followed by 54 J/cm2 light irradiation and measured after 24 hrs by MTT assay	[PMID: 32787080]

In Vitro

Chlorin e6 (100 μg/mL, 24 h) with laser light (635 nm) exhibits no toxicity viability in HT-29 cells^[2].
Chlorin e6 (5-10 μM, 3 h) with near-infrared laser light (660 nm) induces pancreatic cancer cell apoptosis via caspase-3 activation, resulting in tumor growth suppression in AsPC-1 and MIA PaCa-2 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

AsPC-1 and MIA PaCa-2 Cells
Concentration:

5 μM, 10 μM
Incubation Time:

3 h
Result:

Significantly reduced Bcl-2 protein expression while increasing apoptotic molecule expression of Bax.
Activated caspase-3 through its cleavage and upregulated the expression of cleaved PARP-1 in a dose-dependent manner.

In Vivo

Chlorin e6 (2.5 mg/kg, Intravenous injection, single dose) with a red light at a rate of 100 J/cm² for 8 min 20 s has anti-tumor activity in B16F10 melanoma cells and PANC02 Pancreatic Cells xenograft mouse model^[3].
Chlorin e6 (2.5 mg/kg, Intravenous injection, single dose) with near-infrared laser light (660 nm) suppresses the tumor growth in canine tumors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

B16F10 melanoma cells xenograft mouse, PANC02 pancreatic cells xenograft mouse^[3]
Dosage:

2.5 mg/kg
Administration:

Intravenous injection (i.v.)
Result:

Significantly reduced tumor volume.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 19660-77-6
Appearance Solid
분자량 596.67
화학식 C₃₄H₃₆N₄O₆
Color Brown to black
SMILES

OC(C/C1=C2[C@H]([C@@H](C(/C=C3N/C(C(C=C)=C\3C)=C\C4=N/C(C(CC)=C4C)=C\C5=C(C)C(C(O)=O)=C1N5)=N\2)C)CCC(O)=O)=O
Synonyms

Ce6
선적

Room temperature in continental US; may vary elsewhere.
보관

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (20)

All

Sort by:

Journal Impact Factor

ACS Nano

Amplifying X-ray-Induced Charge Transfer Facilitates Direct Sensitization of Photosensitizers in Radiotherapy. [Abstract]

2025 Apr 25. PMID: 40277128
Acta Pharm Sin B

2026 Apr 24.
Adv Sci (Weinh)

Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer. [Abstract]

2025 Nov 21:e10500. PMID: 41270217
Adv Sci (Weinh)

Reprogramming Tumor-Associated Macrophages via Targeted NAT10 Inhibition to Enhance Colorectal Cancer Immunotherapy. [Abstract]

2025 Oct 27:e10854. PMID: 41144699
Adv Sci (Weinh)

Cold-Responsive Hyaluronated Upconversion Nanoplatform for Transdermal Cryo-Photodynamic Cancer Therapy. [Abstract]

2024 May;11(19):e2306684. PMID: 38482992
Chem Eng J

2024 Nov 15.
Biomaterials

Long-acting multiple programmed cell death nanoinducers based on polyunsaturated fatty acid supplemented liposomal photosensitizers for enhanced photodynamic immunotherapy. [Abstract]

2025 Dec 24:329:123948. PMID: 41455306
Sci Adv

A softness zwitterionic micelles efficiently deliver inhaled nintedanib by enhancing airway mucus penetration. [Abstract]

2026 Jan 2;12(1):eady1030. PMID: 41481743
J Control Release

Immunosuppressive-responsive hydrogel for self-regulated drug release and tumor microenvironment reprogramming. [Abstract]

2026 Apr 10:392:114698. PMID: 41692045
J Control Release

Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. [Abstract]

2023 May:357:460-471. PMID: 37068523
Cell Rep Med

Ce6 derivative photodynamic therapy triggers PANoptosis and enhances antitumor immunity with LAG3 blockade in cutaneous squamous cell carcinoma. [Abstract]

2025 Jul 15;6(7):102239. PMID: 40669448
Acta Biomater

Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy. [Abstract]

2026 Apr:214:527-541. PMID: 41796925
Acta Biomater

A Supramolecular Assembly Strategy for Hydrophilic Drug Delivery towards Synergistic Cancer Treatment. [Abstract]

2023 Jul 1:164:407-421. PMID: 37088157
ACS Appl Mater Interfaces

Mitochondrial Rapid Accumulation and Self-Enhanced Penetrating Nanomedicine for Tumor Multi-role Treatment. [Abstract]

2025 Dec 31. PMID: 41476371
ACS Appl Mater Interfaces

Platelet Membrane Biomimetic Chemiluminescent Nanoparticles for Targeted Therapy of Atherosclerosis. [Abstract]

2025 Aug 20;17(33):46680-46692. PMID: 40785258
Int J Pharm X

Biomineralized outer membrane vesicles for synergistic immuno-photodynamic therapy of oral squamous cell carcinoma. [Abstract]

2026 Apr 7:11:100537. PMID: 42028058
Eur J Med Chem

Mitochondria-targeted pentacyclic triterpene NIR-AIE derivatives for enhanced chemotherapeutic and chemo-photodynamic combined therapy. [Abstract]

2024 Jan 15:264:115975. PMID: 38039788
ACS Appl Bio Mater

Feedback-Elevated Antitumor Amplifier of Self-Delivery Nanomedicine by Suppressing Photodynamic Therapy-Caused Inflammation. [Abstract]

2023 Jul 17;6(7):2816-2825. PMID: 37326439
ChemMedChem

Polydopamine-Based Light Responsive Nanoparticles with Magnetic Resonance Imaging Capabilities for Breast Cancer Photodynamic/Photothermal Therapy Combination Therapy. [Abstract]

2026 Jan;21(2):e202500617. PMID: 41619218
Photodiagnosis Photodyn Ther

Regorafenib enhances the efficacy of photodynamic therapy in hepatocellular carcinoma through MAPK signaling pathway suppression. [Abstract]

2024 Aug 22:104319. PMID: 39181490

용액&용해도

In Vitro:

DMSO : 20 mg/mL (33.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6760 mL

8.3798 mL

16.7597 mL

5 mM

0.3352 mL

1.6760 mL

3.3519 mL

10 mM

0.1676 mL

0.8380 mL

1.6760 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (3.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2 mg/mL (3.35 mM); Suspended solution

This protocol yields a suspended solution of ≥ 2 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nie M, et al. Photodynamic inactivation mediated by methylene blue or chlorin e6 against Streptococcus mutans biofilm [J]. Photodiagnosis and photodynamic therapy, 2020, 31: 101817. [Content Brief]

[2]. Karuppusamy S, et al. Nanoengineered chlorin e6 conjugated with hydrogel for photodynamic therapy on cancer [J]. Colloids and Surfaces B: Biointerfaces, 2019, 181: 778-788. [Content Brief]

[3]. Shrestha R, et al. Effect of Photodynamic Therapy with Chlorin e6 on Canine Tumors [J]. Life, 2022, 12(12): 2102. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6760 mL	8.3798 mL	16.7597 mL	41.8992 mL
	5 mM	0.3352 mL	1.6760 mL	3.3519 mL	8.3798 mL
	10 mM	0.1676 mL	0.8380 mL	1.6760 mL	4.1899 mL
	15 mM	0.1117 mL	0.5587 mL	1.1173 mL	2.7933 mL
	20 mM	0.0838 mL	0.4190 mL	0.8380 mL	2.0950 mL
	25 mM	0.0670 mL	0.3352 mL	0.6704 mL	1.6760 mL
	30 mM	0.0559 mL	0.2793 mL	0.5587 mL	1.3966 mL

Chlorin e6

20 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Chlorin e6

Publications Citing Use of MedChemExpress (MCE) Chlorin e6

All Bcl-2 Family Isoforms

All Caspase Isoforms

All PARP Isoforms

Biological Activity

Chemical Information

Publications (20)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Chlorin e6 Related Classifications

HY-13594 Related Classifications